Sino Biopharmaceutical Limited announced positive results from a Phase II clinical trial of TQA3605, a core protein allosteric modulator (CpAM) for the treatment of chronic hepatitis B. The randomized, double-blind, placebo-controlled, multi-center study evaluated the efficacy and safety of TQA3605 in combination with nucleos(t)ide analogues (NAs) in patients with chronic HBV infection and low-level viremia. A total of 122 subjects were enrolled, and the results showed that all TQA3605 dose groups achieved approximately 90% of subjects with HBV DNA levels below the lower limit of quantification (<20 IU/mL), significantly surpassing the NAs monotherapy control group. The safety profile of TQA3605 was generally favorable, with most adverse events reported as Grade 1 to 2 and comparable incidence rates to the control group. The company stated that detailed results from the study will be presented at upcoming international academic conferences.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260127-12002053), on January 27, 2026, and is solely responsible for the information contained therein.
Comments